Glaucoma: CF101 Phase 2 clinical trial in Israel and Europe ongoing. Protocol will be amended and testing will proceed to the second cohort where patients will treated with 2 mg of CF101 or placebo. The company expects to announce full study data in mid-2015.
Dry Eye Syndrome: The firm terminates the development of CF101 for this indication due to the lack of correlation between patients' responses to CF101 and the over-expression of the drug target, the A3 adenosine receptor.
OphthaliX is currently exploring in-licensing opportunities that will complement its ophthalmic diseases pipeline.